



> Return address PO Box 320, 1110 AH Diemen

To the Minister of Health, Welfare and Sport  
PO Box 20350  
2500 EJ THE HAGUE

20240307811

**National Health Care  
Institute**

Care  
Medicinal Products

Willem Dudokhof 1  
1112 ZA Diemen  
PO Box 320  
1110 AH Diemen  
www.zorginstituutnederland.nl  
info@zinl.nl

T +31 (0)20 797 85 55

**Contact**

Date 2 October 2024  
Subject GVS advisory report on 5-fluorouracil 4% cream (Tolak®)

**Our reference**  
2024030781

Dear Ms Agema,

*This is a corrected version of the letter previously sent on 10 September 2024 (reference 20240307811), in which the notation of the standard dose has been adjusted to three decimal places instead of two. This correction has been implemented in the medicine reimbursement system report, which is attached.*

The National Health Care Institute is hereby advising you whether the medicinal product 5-fluorouracil 4% cream (Tolak®) is interchangeable with a medicine already included in the insured package, in the context of a request for it to be placed on List 1A of the Medicine Reimbursement System (hereinafter also "GVS"). The reason we are issuing this advice is the request you made in the letter of 3 September 2024 (CIBG-24-07333).

The considerations are included in the GVS report attached to this letter.

5-fluorouracil 4% cream (Tolak®) is indicated for topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grades I and II) of the face, ears and/or scalp in adults. Actinic keratosis is a skin disorder from which a form of skin cancer (squamous cell carcinoma) develops in 10% of cases over time. 5-fluorouracil 4% cream is available as a cream containing 40 mg 5-fluorouracil per gram (4%). Each pack contains 20 grams of the cream. We have handled this request using a marginal assessment. The considerations are included in the GVS report attached to this letter.

**Advice**

The National Health Care Institute advises you to include 5-fluorouracil 4% cream (Tolak®) for topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grades I and II) of the face, ears and/or scalp in adults in List 1A of the GVS in the existing cluster 0D06BBADC V along with 5-fluorouracil 5%, imiquimod, methyl aminolevulinate and tirbanibulin. The standard dose for 5-fluorouracil 4% should be set at 0.077 g per day.

*Assessment of interchangeability*

Based on the criteria for interchangeability, we conclude that 5-fluorouracil 4% cream (Tolak®) is interchangeable with the other medicinal products in GVS cluster 0D06BBADC V, which includes 5-fluorouracil 5%, imiquimod, methyl aminolevulinate and tirbanibulin.

Should you need any further information, please do not hesitate to contact us.  
The assessment report has been included as an appendix.

Yours sincerely,

Sjaak  
*Chair of the Executive Board*

**National Health Care  
Institute**  
Care  
Medicinal Products

**Date**  
2 October 2024

**Our reference**  
2023004477